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The extracellular matrix (ECM) pro-
vides structural integrity to tissues and
organs and is important for promoting
cell adhesion, migration and survival.
However, changes in the ECM due to
infection, inflammation or wounding
may disrupt the homeostasis of the
extracellular environment. In such
conditions, ECM proteins undergo
proteolytic cleavage or alternative
splicing, resulting in fragmented or
altered forms (1–5). These alterations
lead to aberrant signaling in sur-
rounding cells and catalyze further
degradation of the matrix, exacerbat-
ing the disease. For example, disease-
associated fibronectin fragments can
cause apoptosis and further tissue
catabolism by inducing the expression
of matrix metalloproteinases, nitric
oxide and proinflammatory cytokines
(6–14). The mechanisms by which
ECM fragments elicit these adverse
cellular effects may involve alterations
in receptor regulation and signaling
processes (13,15–18), such as altered
regulation and signaling via p53 and
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Background and Objective: The extracellular matrix (ECM) plays a key role in
signaling necessary for tissue remodeling and cell survival. However, signals from
the ECM altered by disease, e.g. inflammatory diseases such as periodontitis and
arthritis, may lead to apoptosis or programmed cell death of resident cells. Pre-
viously, we found that a disease-associated fibronectin fragment triggers apoptosis
of primary human periodontal ligament cells via a novel apoptotic pathway in
which the tumor suppressor, p53, is transcriptionally downregulated.
Material and Methods: We used immunofluorescence, transfection assays, western
blotting and ELISAs to show that p53 is degraded by a proteasomal pathway in
response to a proapoptotic disease-associated fibronectin fragment.
Results: We found that in these apoptotic conditions, p53 is further downreg-
ulated by post-translational ubiquitination and subsequent targeting to protea-
somes for degradation. Pretreatment of cells with the proteasomal inhibitors
MG132 and lactacystin rescued the cells from apoptosis. The p53 levels in cells
transfected with ubiquitin small interfering RNA were resistant to degradation
induced by the proapoptotic fibronectin fragment, showing that ubiquitination is
important for the proapoptotic fibronectin fragment-induced degradation of
p53.
Conclusion: These data show that a proapoptotic fibronectin matrix induces
ubiquitination and degradation of p53 in the proteasome as part of a novel
mechanism of apoptosis associated with inflammatory diseases.
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the c-Jun NH2-terminal stress-related
kinases (13,16,17,19).
The existence of fibronectin frag-
ments has been documented in chronic
inflammatory diseases and shown to be
important in the pathogenesis of
chronic inflammation, including
arthritis and periodontal disease
(1,2,5–7,14,15). We generated and
characterized several recombinant
counterparts of the fibronectin frag-
ments that are found in in vivo condi-
tions (9). One such fibronectin
fragment is defective in binding to
heparin. We found that while the na-
tive fibronectin molecule promotes
growth and attachment of cells, the
defective form of the fibronectin frag-
ment triggered cell detachment and
showed a proapoptotic effect, since it
induced apoptotic cell shape changes
and apoptotic cell signaling. Cells
treated with this proapoptotic fibro-
nectin fragment showed a decrease in
p53 at both the transcriptional and the
protein levels (2,11–13,15).
The transcription factor p53 is a
tumor suppressor that plays a critical
role in safeguarding the integrity of the
genome (20) and controls cell-cycle
arrest, apoptosis and cellular senes-
cence (21). Its expression and activa-
tion are tightly controlled within the
cell by post-translational modifica-
tions, including ubiquitination, acety-
lation and phosphorylation (22).
Often, p53 regulatory networks are
perturbed by stress signals, such as
DNA damage, oncogene activation,
hypoxia and nitric oxide production,
resulting in ubiquitination of p53 (23)
and its degradation in the proteasome
(24,25).
As mentioned above, the reduction
in p53 promoter activity and mRNA
level in cells exposed to the proapop-
totic fibronectin fragment was not
sufficient to explain the significant loss
of p53 protein. Thus, we hypothesized
that the decrease in p53 levels in cells
treated with the proapoptotic fibro-
nectin fragment was also due to post-
translational modifications. One of the
prevalent modes of p53 downregula-
tion is through its ubiquitination,
which targets it to the proteasome for
degradation (26). Currently, there is no
literature describing the type of post-
translational modification undergone
by p53 that accentuates its degradation
in response to inflammation/disease-
associated extracellular matrix proteins
or their fragments. Therefore, this
study was initiated to investigate whe-
ther fibronectin fragments induce
ubiquitination of p53 and its degrada-
tion through the proteasome.
Material and methods
Primary periodontal ligament (PDL)
cell culture
Human primary PDL cells were
isolated and cultured as described (12).
The PDL cells were isolated from the
teeth that were extracted from patients
undergoing treatment at the School
of Dentistry, University of Michigan,
Ann Arbor, USA. The donors
provided written consent and these
were in accordance with the University
of Michigan Health Sciences Institu-
tional Review Board. Their use was
approved by the University of Michi-
gan Health Sciences Institutional
Review Board. Cells were maintained
in a-minimal essential medium (Invi-
trogen, Carlsbad, CA, USA) contain-
ing 10% fetal calf serum (Hyclone,
Logan, UT, USA) and penicillin (100
U/mL) and streptomycin (100 lg/mL).
Recombinant fibronectin proteins
For these studies, we used two previ-
ously described recombinant fibronec-
tin fragments (10) that contain the
alternatively spliced V region (V+) and
either an intact (H+) or a mutated,
non-functional (H)) high-affinity hep-
arin-binding domain. The control
fibronectin fragment (CFn), with the
intact H+ domain, and the proapop-
totic fragment (AFn), with the mutated
H) domain, were used at a concentra-
tion of 0.1 mM. The proapoptotic
fragment is comparable to the disease-
associated 40 kDa proteolytic
fragment, also shown by our group to
induce apoptosis in PDL cells.
Western blot analysis
For western blot analysis, cells were
lysed in RIPA buffer (Sigma, St Louis,
MO, USA) containing protease inhibi-
tors (Sigma). Protein concentration was
determined by the BCA protein assay
kit (Pierce, Rockford, IL, USA). Equal
amounts of protein were resolved by
standard procedures using SDS-PAGE
with 4–20% gels (Novex; Invitrogen)
and electroblotted onto polyvinylidene
membranes (PVDF; Immobilon-P;
Millipore, Billerica,MA,USA) by semi-
dry transfer blot (Bio-Rad, Hercules,
CA, USA) according to the manufac-
turers instructions. The primary anti-
bodies were mouse anti-human p53–
horseradish peroxidase (DO-1), rabbit
anti-human ubiquitin and goat anti-
human actin (I-19; Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Immunoprecipitation
For immunoprecipitation, cells treated
with AFn or CFn fragments, or control
serum-free medium, in the presence or
absence of lactacystin, were lysed in
RIPA buffer containing protease
inhibitors. Equal amounts of protein
from the lysates were precleared with
protein G–agarose (Amersham Bio-
sciences, Little Chalfont, Buckingham-
shire, UK), incubated with mouse
anti-p53 overnight at 4C and then with
protein G–agarose beads for 2 h. After
five washes with RIPA buffer, the beads
were boiled in SDS-PAGE reducing
sample buffer. Supernatants were
resolved by SDS-PAGE with 4–20%
gels and processed for western blot
analysis. After incubation of the PVDF
membranes with anti-ubiquitin anti-
bodies, the blots were incubated with
Clean Blot HRP reagent (Pierce),
which recognized only the native pri-
mary antibodies and did not interact
with the denatured primary antibodies
(IgG) that were used to immunopre-
cipitate the p53 molecules.
Small interfering RNA (siRNA)
transfection experiments
One day before transfection, cells were
plated at 60% confluency in six-well
dishes. Human ubiquitin UBA52
siRNA (Dharmacon, Thermo Fisher
Scientific, Freemont, CA, USA;
NM_003333) or the control siRNA
(Dharmacon) were introduced into
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cells using Lipofectamine 2000 (Invi-
trogen) as recommended by the man-
ufacturer. Thirty-six hours post-
transfection, cells were treated with the
fibronectin fragments in serum-free
medium for 7 h and processed for
western blot analysis.
Immunofluorescence
To immunolocalize p53, cells were
fixed with 3% paraformaldehyde in
phosphate-buffered saline, pH 7.2,
permeabilized with 0.1% Triton X-100
in phosphate-buffered saline for
20 min and incubated in 5% bovine
serum albumin in Tris Buffered Saline
Tween (TBST) (25 mM Tris, 150 mM
NaCl, 0.05% Tween-20) for 1 h at
room temperature. Cells were then
incubated with mouse anti-p53 (DO-1)
overnight at 4 C, washed with TBST,
treated with fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse
antibody for 1 h at room temperature
and washed with TBST. Then cells
were stained with 4¢,6¢-diamidino-2-
phenylindole (DAPI; Sigma) for
10 min, rinsed with calcium- and
magnesium-free phosphate-buffered
saline, air dried, mounted on glass
slides with Vectashield (Vector Labo-
ratories, Burlingame, CA, USA), and
examined with a Nikon TS100 photo-
microscope.
Apoptosis ELISA assay
Cells were pretreated with lactacystin
and then treated with proapoptotic or
control fibronectin fragment or control
media. Thereafter, the cells were lysed,
and equal amounts of cell lysate pro-
tein were processed to quantify apop-
tosis using the Cell Death Detection
ELISAPLUS kit (Roche, Mannheim,
Germany) as recommended by the
manufacturer.
Other reagents
The proteasomal inhibitors, lactacystin
and MG132, were from Calbiochem
(La Jolla, CA, USA). All other chemi-
cals were from Sigma unless mentioned
otherwise.
Results
A fragmented fibronectin matrix
triggers p53 degradation through a
proteasomal pathway
In our previous studies, we observed
that a recombinant fibronectin frag-
ment, which is comparable to its in vivo
proteolytic counterpart found in
inflammatory gingival crevicular fluids,
causes a decrease in p53 levels as part
of a unique apoptosis pathway. How-
ever, only part of the reduction in p53
levels could be explained by transcrip-
tional downregulation (11), suggesting
that other protein degradation path-
ways, such as the lysosomal and pro-
teasomal pathways (27,28), may be
contributing to the elimination of p53
when cells are treated with the
proapoptotic fibronectin fragment
(AFn). First, we pre-incubated PDL
cells with different lysosomal enzyme
inhibitors before treating cells with the
AFn and then examined the cell lysates
for p53 protein levels by western blot
analysis. As seen in Fig 1A, pretreat-
ment of cells with lysosomal enzyme
inhibitors failed to prevent p53 degra-
dation in response to treatment with
AFn (lanes 3–12), suggesting that p53
was not being degraded through the
lysosomal pathway. Moreover, p53
was also degraded (Fig. 1A, lane 14) in
cells pretreated with cycloheximide, a
protein synthesis inhibitor, suggesting
that new protein synthesis is not
required for the degradation of p53 in
this pathway.
In addition to the lysosome, the
proteasome is an important compo-
nent of the cell machinery that medi-
ates protein degradation. Protein
degradation is vital for initiating, ter-
minating and regulating many cellular
processes, and the proteasome is
involved in this degradation process.
One of the most important regulatory
1 2 3 4 5 6
PI (nM)+M +M +M +M +M +M +M




























1   2 4 5 63
Actin
p
0 10 20 30 40 50
A B
C
Fig. 1. Proapoptotic fibronectin induces p53 degradation through the proteasomal pathway. (A) Human primary periodontal ligament
(PDL) cells were pre-incubated with serum-free medium, 10 lM chloroquine (CQ), 100 lM pepstatin A (PS), 100 lM leupeptin (LP), 50 nM
bafilomycin A (BF), 10 lM monensin (MN) or 10 lM cycloheximide (CH), for 2 h and then treated with AFn (+) or control medium (M) in
presence of the drugs for 7 h. Cells were then lysed, and the lysates were resolved by SDS-PAGE, immunoblotted with an anti-p53 antibody,
and visualized by chemiluminescence. (B) Cells were treated with various concentrations of MG132 (PI) for 7 h, lysed, and analyzed by
western immunoblotting to determine the concentration that resulted in the highest level of p53. (C) Cells were pretreated with 30 nM MG132
(PI) for 2 h and then with recombinant fibronectin fragment, AFn, or control fibronectin fragment, CFn, for 7 h. The cells were then lysed,
and the p53 levels were determined by western blotting. Actin served as a loading control.
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proteins in the cell is p53, and its level
is tightly regulated by transcriptional
and post-translational modifications
(21). In many an instance, the degra-
dation of p53 in cells is mediated by the
proteasome (22). Therefore, to ascer-
tain whether the degradation of p53 in
response to AFn was mediated by the
proteasome, we pretreated cells with
MG132, a proteasome inhibitor,
before treating the cells with AFn.
First, we determined that 30 nM was
the optimal concentration of MG132,
which on its own did not induce cel-
lular toxicity (Fig. 1B, lane 4). There-
after, we pretreated cells with 30 nM
MG132 for 2 h prior to treating them
with AFn for a further 7 h. We
observed that inhibiting the protea-
some with MG132 prevented the deg-
radation of endogenous p53 in
response to AFn (Fig. 1C, lanes 2 and
5). Control medium or a control
fibronectin fragment (CFn) did not
alter the p53 levels (Fig. 1C, lanes 1
and 3). From these experiments, we
concluded that the degradation of p53
in cells treated with the AFn is medi-
ated through the proteasome.
In earlier studies (9, 11–13), we
showed that primary PDL cells under-
went apoptosis when treated with AFn.
We observed that cells overexpressing
p53 were less susceptible to apoptosis.
Since, in this present study (Fig. 1) we
observed that inhibition of the protea-
some resulted in stabilization of p53, we
tested whether this approach could be
used as an alternative to overexpressing
p53 to rescue the cells from apoptosis.
Indeed, pretreatment of cells with
MG132 prior to exposure of cells to the
AFn prevented cell rounding, nuclear
condensation and fragmentation, the
hallmarks of apoptosis (11; Fig. 2A).
There were also strong nuclear signals
for p53 in cells that were pretreated
with proteasome inhibitor and incu-
bated with the AFn. This showed that
primary cells could resist apoptosis in-
duced by the AFn if the proteasomal
degradation of p53 was halted. In fact,
clinical trials testing proteasome inhib-
itors have shown that this may be a
viable treatment for chronic inflam-
mation (29–31).
To further show that proteasome
inhibitors, by virtue of their ability to
inhibit the degradation of endogenous
p53, can rescue cells from apoptosis,
we pretreated cells with lactacystin,
another proteasomal inhibitor, and
measured the fold change in apoptosis
in cells exposed to AFn. As shown in
Fig. 2B, apoptosis, measured by an
ELISA assay, which measures cyto-
plasmic histone-associated DNA frag-
ments, was substantially reduced by
the pretreatment of cells with lacta-
cystin.
Downregulation of p53 by a
fragmented fibronectin matrix is
mediated by ubiquitination
Prior to degradation, p53 undergoes
ubiquitination (24), and in cells treated
with proteasomal inhibitors, such as
MG132 or lactacystin, there is an
accumulation of multi-ubiquitinated
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Fig. 2. A proteasome inhibitor rescues cells from apoptosis induced by proapoptotic fibronectin. (A) Human primary periodontal ligament
cells (PDL) were pretreated for 2 h with 30 nM MG132 (PI) or control medium (Media) and then with the recombinant fibronectin fragment,
AFn, or control fibronectin fragment, CFn, for 7 h. Subsequently, the cells were fixed, and p53 expression (FITC) and nuclear morphology
(DAPI) were visualized by immunofluorescence and phase-contrast microscopy. Scale bar = 50 lm. (B) Human primary PDL cells were
pretreated for 2 h with 10 lM lactacystin (PI) or control medium and then with the recombinant fibronectin fragments or control medium for
7 h. The cells were lysed, and cell death was determined using Cell Death Detection ELISAPLUS (Roche) as outlined by the manufacturer.
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pretreatment of cells with the protea-
some inhibitor lactacystin also stabi-
lized p53 and prevented its degradation
(Fig. 3A, lanes 4, 5 and 6). In the ab-
sence of lactacystin, cells treated with
the AFn had lower levels of p53
(Fig. 3A, lane 4). Since treatment with
a proteasomal inhibitor can result in
the accumulation of multi-ubiquiti-
nated p53 molecules, we examined this
possibility in our system. We immu-
noprecipitated the proteins shown in
Fig. 3A with an anti-p53 antibody and
probed them with an antibody to
ubiquitin. We observed a ladder of
bands in cells pretreated with lacta-
cystin, and these were, in fact, different
ubiquitinated forms of p53, since they
were recognized by an anti-ubiquitin
antibody after immunoprecipitating
them with an anti-p53 antibody. Fur-
thermore, cells that were treated with
AFn and lactacystin had more ubiqui-
tinated p53 forms (Fig. 3B, lane 3)
than the cells treated with lactacystin
alone (Fig. 3B, lane 4).
From the preceding experiments, it
was clear that the major site for the
degradation of p53 in cells, which were
exposed to AFn, was the proteasome
(Figs. 1)3). When destined for degra-
dation, p53 gets ubiquitinated, and
ubiquitinated p53 is a substrate for the
proteasome (20,22,32–34). We had also
observed the presence of ubiquitinated
p53 in cells that were treated with
proteasome inhibitor and AFn.
Therefore, to confirm the participation
of ubiquitin in the degradation of p53
induced by AFn, we transfected cells
with siRNA for ubiquitin. As seen in
Fig. 4A, ubiquitin expression was sig-
nificantly reduced in cells transfected
with ubiquitin siRNA (Fig. 4A,
lane 3). Next, cells were transfected
with ubiquitin siRNA and then treated
with the AFn (Fig. 4B). In cells trans-
fected with ubiquitin siRNA, there was
less ubiquitination of p53 and conse-
quently higher levels of p53 (Fig. 4B,
lane 2) compared with cells that were
treated with the control siRNA
(Fig. 4B, lane 1). Moreover, cells with
suppressed levels of ubiquitin had
higher levels of p53 even in the pres-
ence of AFn (Fig. 4B, lane 4) com-
pared with cells transfected with a


































Fig. 3. A proteasomal inhibitor, lactacystin, inhibits ubiquitin-mediated p53 degradation
induced by proapoptotic fibronectin. Human primary periodontal ligament cells were pre-
treated for 2 h with lactacystin (PI) or control medium, and treated with fibronectin frag-
ment, AFn, or control medium for 7 h. (A) Cell lysates were analyzed by immunoblotting to
determine the level of p53. Actin served as a loading control. (B) The lysates of lanes 1, 3, 4


























































Fig. 4. Cells transfected with ubiquitin siRNA are resistant to proapoptotic fibronectin-
induced p53 degradation. (A) Primary periodontal ligament (PDL) cells were transfected
with ubiquitin (UB) siRNA to inhibit ubiquitin expression. The level of ubiquitin expression
was analyzed by western blotting with anti-ubiquitin antibody 36 h after transfection.
(B) Cells were transfected with ubiquitin siRNA or control siRNA for 36 h and then treated
with AFn or control medium for 7 h. Cell lysates were prepared, and p53 expression was
analyzed by western blotting with an anti-p53 antibody. Actin served as a loading control.
(C) Primary PDL cells were transfected with ubiquitin or control siRNA as in (A) and then
treated with AFn or control serum-free medium. Equal amounts of cell lysates (by protein)
were used to determine cell death using Cell Death Detection ELISAPLUS (Roche) as outlined
by the manufacturer.
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cating that ubiquitination of p53 is
important for its degradation in this
process. In addition to mitigating the
degradation of p53 mediated by AFn,
inhibition of ubiquitin expression also
blocked the apoptosis of cells initiated
by AFn, as shown in Fig. 4C. The
residual apoptosis seen in ubiquitin
siRNA transfected cells in the presence
of AFn might be attributed to the
remaining low level of ubiquitin
expression that was observed in these
cells (Fig. 4A, lane 3).
Discussion
The ECM is composed of several
macromolecules, which play an
important role in development, differ-
entiation and cell–cell communication
and signaling events. Fibronectin, a
major constituent of the ECM, is
present in the matrix of a variety of
connective tissues and its alternatively
spliced forms are most commonly
found during embryonic development
and tissue remodeling. It usually exists
as a dimer, consisting of similar but not
necessarily identical chains, and each
polypeptide chain is approximately
250 kDa in size. It has several do-
mains, including the collagen/gelatin-,
heparin- and central cell-binding do-
mains, each of which has multiple
functions (35). Proteolytic cleavage of
fibronectin by proteases found in
inflammatory fluids yields an array of
fibronectin fragments. One such fibro-
nectin fragment is comparable to AFn.
Our present study shows that when
PDL cells are treated with this fibro-
nectin fragment, p53 gets ubiquitinated
and degraded in the proteasome.
Treatment with the proteasome inhibi-
tor MG132 markedly inhibited the
decrease in p53 protein levels induced
by this fibronectin fragment and re-
sulted in the accumulation of multiple
species of ubiquitinated p53 molecules.
The same was seen with lactacystin, an
irreversible inhibitor of the protea-
some. After treatment with AFn, p53
levels were higher in cells transfected
with ubiquitin siRNA than in un-
transfected cells, demonstrating that
ubiquitination is necessary for the
degradation of p53 by this fibronectin
fragment. Treatment of cells with a
protein synthesis inhibitor or a lyso-
somal inhibitor did not prevent p53
degradation. Thus, the degradation did
not involve the lysosomal pathway.
Our immunofluorescence data further
confirmed that pretreatment of cells
with proteasome inhibitors can rescue
the downregulation of p53 and conse-
quent rounding and apoptosis of cells
triggered by the fibronectin fragment.
This was additionally confirmed by the
ELISA data, which clearly showed that
pretreating cells with a proteasome
inhibitor greatly reduced the apoptosis
of AFn-treated PDL cells. Slight
apoptosis observed in control fibro-
nectin fragment-treated cells is proba-
bly due to serum starvation of the cells.
Our results showing that proapop-
totic fibronectin fragment-induced p53
degradation is ubiquitin dependent are
in agreement with previous findings. In
these reports, ubiquitination of p53 is
necessary for its degradation through
the proteasome (32–34). In conclusion,
apoptosis mediated by a proapoptotic
fibronectin fragment involves the asso-
ciation of p53 with ubiquitin and its
subsequent degradation by the protea-
some. Inhibiting either the proteolytic
function of the proteasome or sup-
pressing ubiquitin at its protein level
prevented the degradation of p53 and
subsequent apoptosis of these primary
PDL cells. These findings provide po-
tential therapeutic targets and strategies
for addressing inflammatory diseases
such as arthritis and periodontal disease
that manifest alterations in the ECM.
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